Log In
BCIQ
Print this Print this
 

Deberza, tofogliflozin (CSG452) (formerly R7201, RG7201)

  Manage Alerts
Collapse Summary General Information
Company Chugai Pharmaceutical Co. Ltd.
DescriptionSodium-glucose transporter 2 (SGLT2) inhibitor
Molecular Target Sodium-glucose cotransporter 2 (SGLT2)
Mechanism of ActionSodium-glucose cotransporter 2 (SGLT2) inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationDiabetes
Indication DetailsTreat Type II diabetes
Regulatory Designation
PartnerKowa Co. Ltd.;
Kowa Co. Ltd.;
Sanofi

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

11/05/2012

Undisclosed

0

Undisclosed

Get a free BioCentury trial today